Compare CBL & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CBL | NTLA |
|---|---|---|
| Founded | 1978 | 2014 |
| Country | United States | United States |
| Employees | 500 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 1995 | 2016 |
| Metric | CBL | NTLA |
|---|---|---|
| Price | $47.30 | $14.04 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 23 |
| Target Price | ★ $45.00 | $20.02 |
| AVG Volume (30 Days) | 162.7K | ★ 6.1M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.00% | N/A |
| EPS Growth | ★ 132.09 | 27.43 |
| EPS | ★ 4.34 | N/A |
| Revenue | ★ $578,373,000.00 | $67,671,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $62.75 |
| P/E Ratio | $10.10 | ★ N/A |
| Revenue Growth | 12.18 | ★ 16.92 |
| 52 Week Low | $24.03 | $6.83 |
| 52 Week High | $45.86 | $28.24 |
| Indicator | CBL | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 74.02 | 51.33 |
| Support Level | $36.41 | $11.51 |
| Resistance Level | N/A | $14.02 |
| Average True Range (ATR) | 1.23 | 1.21 |
| MACD | -0.07 | -0.07 |
| Stochastic Oscillator | 88.05 | 43.25 |
CBL & Associates Properties Inc is a real estate investment trust. The company engages in the ownership, development, acquisition, leasing, management and operation of regional shopping malls, outlet centers, lifestyle centers, open-air centers and other properties. CBL's sales predominantly derive from leasing arrangements with retail tenants. The company also generates revenue from management and development fees, as well as sales of its real estate assets. CBL expands its portfolio of assets through activities such as redevelopment, renovation, and expansion.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.